Primary tumors of the central nervous system, gliomas, are notoriously difficult to control, due in large measure to their highly invasive behavior. The ability of cells to migrate through tissue depends, in part, on the composition of the tissues extracellular matrix (ECM). Understanding the molecular composition of the extracellular environment of brain tumors is one approach to developing methods to prevent tumor invasion. BEHAB/brevican, a recently identified brain-specific ECM protein, is markedly upregulated in human glioma and in experimental models of glioma. In human glioma BEHAB/brevican expression is 700 percent over that in the normal adult human brain and expression is not detected in any non-glial derived tumor, even when these tumors grow within the brain. Our work during the previous funding period has provided evidence that BEHAB/brevican plays a role in glioma invasion. The experiments proposed here will test this hypothesis and, in addition, will test the possibility that BEHAB/brevican may provide a novel therapeutic target for glioma. In experimental glioma cel models, BEHAB/brevican expression is induced by a brain-specific factor. The first specific aim of this application is to characterize the mechanism of BEHAB/brevican induction and to identify potential inducing factors. Several converging lines of evidence suggest that proteolytic processing is required for BEHAB/brevican function in glioma invasion. The second specific aim of this application is to characterize BEHAB/brevican Droteolytic cleava2e in glioma. Slowing or preventing glioma cell motility could increase the efficacy of regional therapies; the third specific aim of this application is to determine whether inhibitors of BEHAB/brevican cleavage can slow tumor invasion and, therefore, might provide a new therapeutic avenue foi glioma. Our work has led to the hypothesis that production, cleavage, and turnover of BEHAB/brevican together modulate the ECM and can regulate cell motility. Our final specific aim is to test a role for BEHAB/brevican turnover in glioma invasion. Our long-term goal is to determine if functional reduction or elimination of BEHAB could slow the progression of primary brain tumor.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS035228-07
Application #
6613311
Study Section
Special Emphasis Panel (ZRG1-MDCN-2 (01))
Program Officer
Finkelstein, Robert
Project Start
1996-05-01
Project End
2005-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
7
Fiscal Year
2003
Total Cost
$408,750
Indirect Cost
Name
Yale University
Department
Neurosciences
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Dwyer, Chrissa A; Bi, Wenya Linda; Viapiano, Mariano S et al. (2014) Brevican knockdown reduces late-stage glioma tumor aggressiveness. J Neurooncol 120:63-72
Viapiano, Mariano Sebastian; Hockfield, Susan; Matthews, Russell Thomas (2008) BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion. J Neurooncol 88:261-72
Viapiano, Mariano S; Bi, Wenya Linda; Piepmeier, Joseph et al. (2005) Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res 65:6726-33
Viapiano, Mariano S; Matthews, Russell T; Hockfield, Susan (2003) A novel membrane-associated glycovariant of BEHAB/brevican is up-regulated during rat brain development and in a rat model of invasive glioma. J Biol Chem 278:33239-47
Nutt, C L; Matthews, R T; Hockfield, S (2001) Glial tumor invasion: a role for the upregulation and cleavage of BEHAB/brevican. Neuroscientist 7:113-22
Nutt, C L; Zerillo, C A; Kelly, G M et al. (2001) Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats. Cancer Res 61:7056-9
Gary, S C; Zerillo, C A; Chiang, V L et al. (2000) cDNA cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma. Gene 256:139-47
Matthews, R T; Gary, S C; Zerillo, C et al. (2000) Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. J Biol Chem 275:22695-703
Gary, S C; Kelly, G M; Hockfield, S (1998) BEHAB/brevican: a brain-specific lectican implicated in gliomas and glial cell motility. Curr Opin Neurobiol 8:576-81
Zhang, H; Kelly, G; Zerillo, C et al. (1998) Expression of a cleaved brain-specific extracellular matrix protein mediates glioma cell invasion In vivo. J Neurosci 18:2370-6